Evonik's Strategic Challenges Amid Geopolitical and Market Pressures

German chemical industry faces uncertainty as VCI withdraws 2026 forecast due to Iran conflict supply risks. Evonik stock oversold amid sector split and Asian competition.

The German chemical industry faces a period of significant uncertainty. The Chemical Industry Association (VCI) has formally withdrawn its 2026 forecast, citing the threat of supply chain disruptions stemming from the Iran conflict. For a major player like Evonik, whose manufacturing processes rely on stable raw material inputs, this is a direct and tangible business risk.

Operational Headwinds and a Divided Sector

Recent industry data underscores the difficult environment. Fourth-quarter 2025 figures reveal a sector split in performance. Pharmaceutical chemical production showed gains, but basic chemical manufacturing continued its downward trajectory. This segment saw declines in production, prices, and sales, with capacity utilization remaining below profitability thresholds. Overall, the industry's total revenue fell by 2.8% year-on-year to 51.8 billion euros.

Compounding the geopolitical supply concerns is intense structural pressure from Asian competitors. Producers in China and elsewhere are exerting severe pricing pressure, creating substantial challenges for European chemical companies. In response, Evonik is pursuing strategic countermeasures. Its recent move to expand a distribution partnership for Visiomer products in the United States market signals an intent to offset weakness in its European home base by strengthening its international footprint.

Technical Indicators Suggest Oversold Conditions

From an investment perspective, Evonik's equity has had a difficult run, shedding approximately one-third of its value over a twelve-month period. The stock's Relative Strength Index (RSI) currently stands at 20.1, placing it firmly in oversold territory. While this technical reading often hints at the potential for a short-term price recovery, it does not, in itself, indicate a fundamental improvement in the company's outlook.

The path forward remains clouded. Planning certainty for the conglomerate is likely to remain constrained as long as raw material risks linked to the Iran conflict persist and the VCI refrains from issuing a new annual projection. Upcoming quarterly results will be scrutinized for evidence that operational stabilization within Evonik's pharmaceutical segment is sufficient to cushion the broader burdens facing the business.